An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients with Knee Joint Osteoarthritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs MIV 711 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Medivir AB
- 14 Sep 2017 According to a Medivir AB media release, the independent Data Monitoring Committee (DMC) has again recommended continuation of the extension study without modifications, based on the planned final review of the accumulated safety data.
- 24 Aug 2017 Planned End Date changed from 1 Feb 2018 to 1 Dec 2017.
- 25 Jul 2017 According to a Medivir AB media release, data from this study will be available in the first quarter of 2018.